Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 7/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.83 |
| ▸ | HTR2A | P28223 | 9/20 | 0.76 |
| ▸ | HTR1A | P08908 | 6/20 | 0.68 |
| ▸ | HTR2C | P28335 | 4/20 | 0.68 |
| ▸ | HTR1D | P28221 | 6/20 | 0.67 |
| ▸ | HTR1B | P28222 | 5/20 | 0.67 |
| ▸ | HTR1E | P28566 | 3/20 | 0.65 |
| ▸ | HTR7 | P34969 | 3/20 | 0.65 |
| ▸ | HTR2B | P41595 | 3/20 | 0.65 |
| ▸ | HTR5A | P47898 | 3/20 | 0.65 |
| ▸ | HTR6 | P50406 | 3/20 | 0.65 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.65 |
| ▸ | HTR3B | O95264 | 2/20 | 0.65 |
| ▸ | HTR1F | P30939 | 2/20 | 0.65 |
| ▸ | HTR3A | P46098 | 2/20 | 0.65 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.65 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.65 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29904417 | 1.00 | MPO (1.00) | MPOSLC6A4HTR2AHTR1AHTR2C | |
| SCHEMBL2615141 | 1.00 | MPO (1.00) | MPOSLC6A4HTR2AHTR1AHTR2C | |
| Hydrochloric Acid SCHEMBL32677865 | 0.98 | MPO (0.97) | MPOSLC6A4HTR2AHTR1AHTR2C | |
| Hydrochloric Acid SCHEMBL32677864 | 0.98 | MPO (0.97) | MPOSLC6A4HTR2AHTR1AHTR2C | |
| SCHEMBL7324098 | 0.88 | MPO (0.79) | MPOSLC6A4HTR2AHTR1AHTR2C | |
| SCHEMBL23927849 | 0.88 | MPO (0.78) | MPOSLC6A4HTR2AHTR1AHTR2C | |
| SCHEMBL29435343 | 0.88 | MPO (0.78) | MPOSLC6A4HTR2AHTR1AHTR2C | |
| SCHEMBL29904441 | 0.87 | HTR2A (1.00) | MPOSLC6A4HTR2AHTR1AHTR2C | |
| SCHEMBL24243693 | 0.87 | HTR2A (1.00) | MPOSLC6A4HTR2AHTR1AHTR2C | |
| SCHEMBL2405551 | 0.86 | MPO (0.75) | MPOSLC6A4HTR2AHTR1AMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260090957-A1 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | DRESDNER JR KARL P (US) | 2026-04-02 | — | — | US | claimed |
| EP-4358962-B1 | TREATMENT FOR AUTOIMMUNE DISEASES COMPRISING NALTREXONE OR A METABOLITE OR ANALOG THEREOF, A CANNABINOID AND A 5-HT RECEPTOR AGONIST | LDN PHARMA LTD (GB) | 2026-02-04 | — | — | EP | claimed |
| US-20250281481-A1 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILTY OF 5-HT RECEPTOR AGONISTS | LDN Pharma Limited (GB) | 2025-09-11 | — | — | US | claimed |
| US-12343337-B2 | Compounds for increasing neural plasticity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-01 | — | — | US | claimed |
| US-20240293395-A1 | NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B or 2C AGONISTS | LDN Pharma Limited (GB) | 2024-09-05 | — | — | US | claimed |
| US-20240285612-A1 | COMPOSITIONS COMPRISING AN AGONIST OF 5-HYDROXYTRYPTAMINE (5-HT) RECEPTOR SUBTYPE 3 | LDN Pharma Limited (GB) | 2024-08-29 | — | — | US | claimed |
| US-20240285613-A1 | TREATMENT FOR AUTOIMMUNE DISEASES | LDN Pharma Limited (GB) | 2024-08-29 | — | — | US | claimed |
| EP-4358960-A1 | COMPOSITIONS COMPRISING AN AGONIST OF 5-HYDROXYTRYPTAMINE (5-HT) RECEPTOR SUBTYPE 3 | LDN Pharma Limited (GB) | 2024-05-01 | — | — | EP | claimed |
| EP-4358943-A1 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILITY OF 5-HT RECEPTOR AGONISTS | LDN Pharma Limited (GB) | 2024-05-01 | — | — | EP | claimed |
| EP-4358961-A1 | NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B OR 2C AGONISTS | LDN Pharma Limited (GB) | 2024-05-01 | — | — | EP | claimed |
| EP-4358962-A1 | TREATMENT FOR AUTOIMMUNE DISEASES | LDN Pharma Limited (GB) | 2024-05-01 | — | — | EP | claimed |
| WO-2022269264-A1 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILITY OF 5-HT RECEPTOR AGONISTS | LDN Pharma Limited (GB) | 2022-12-29 | — | — | WO | claimed |
| WO-2022269267-A1 | TREATMENT FOR AUTOIMMUNE DISEASES | LDN Pharma Limited (GB) | 2022-12-29 | — | — | WO | claimed |
| WO-2022269266-A1 | NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B OR 2C AGONISTS | LDN Pharma Limited (GB) | 2022-12-29 | — | — | WO | claimed |
| WO-2022269265-A1 | COMPOSITIONS COMPRISING AN AGONIST OF 5-HYDROXYTRYPTAMINE (5-HT) RECEPTOR SUBTYPE 3 | LDN Pharma Limited (GB) | 2022-12-29 | — | — | WO | claimed |
| US-20260090957-A1 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | DRESDNER JR KARL P (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4358962-B1 | TREATMENT FOR AUTOIMMUNE DISEASES COMPRISING NALTREXONE OR A METABOLITE OR ANALOG THEREOF, A CANNABINOID AND A 5-HT RECEPTOR AGONIST | LDN PHARMA LTD (GB) | 2026-02-04 | — | — | EP | disclosed |
| WO-2010151258-A1 | METHODS OF TREATING PSYCHOLOGICAL CONDITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010136546-A1 | 3-ALKYL-5-FLUOROINDOLE DERIVATIVES AS MYELOPEROXIDASE INHIBITORS | Université Libre de Bruxelles (BE) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010081036-A2 | FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293395-A1 | NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B or 2C AGONISTS | HTR2C, HTR2B, HTR2A | MPO 4431/4885SLC6A4 35/4885HTR2A 3/4885 |
| US-12343337-B2 | Compounds for increasing neural plasticity | PNMT, GAP43, SLC18A2 | MPO 4338/4885SLC6A4 71/4885HTR2A 10/4885 |
| US-20250281481-A1 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILTY OF 5-HT RECEPTOR AGONISTS | VDR, OPRD1, HTR1A | MPO 3342/4885SLC6A4 44/4885HTR2A 11/4885 |
| US-20240285612-A1 | COMPOSITIONS COMPRISING AN AGONIST OF 5-HYDROXYTRYPTAMINE (5-HT) RECEPTOR SUBTYPE 3 | HTR3A, HTR3C, HTR1A | MPO 4311/4885SLC6A4 27/4885HTR2A 10/4885 |
| US-20260090957-A1 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | QPCT, SLC38A7, QPCTL | MPO 2988/4885SLC6A4 440/4885HTR2A 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.